Amyloid-beta Fibril Formation Pathway

Migration, Crosslink

📖

Amyloid-beta Fibril Formation Pathway

active

wiki page Created: 2026-04-02T07:20:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-amyloid-beta-fibril-form

📖 Wiki Page

mechanism3761 wordssynced 2026-04-02

Amyloid-beta Fibril Formation Pathway

Overview

Amyloid-beta (Aβ) fibril formation represents a defining pathological hallmark of Alzheimer's disease (AD). These insoluble, β-sheet-rich structures aggregate to form amyloid plaques that have been used for decades as a diagnostic criterion for postmortem AD diagnosis. Recent cryo-electron microscopy (cryo-EM) studies have revealed the atomic structures of Aβ fibrils, providing unprecedented insight into the molecular architecture of these disease-associated aggregates [@sawaya2014][@gremer2017][@jiang2019].

The term "amyloid" was first coined by Rudolf Virchow in 1854 to describe the waxy, starch-like deposits observed in various organs [@virchow1854]. Over a century later, the fundamental structural principle underlying all amyloid fibrils was identified: the cross-β architecture, where β-strands run perpendicular to the fibril axis, forming β-sheets that stack through hydrogen bonding [@sunde1997]. This common structure explains why diverse proteins with different amino acid sequences can form morphologically similar fibrils with distinct biological activities.

...

Amyloid-beta Fibril Formation Pathway

Overview

Amyloid-beta (Aβ) fibril formation represents a defining pathological hallmark of Alzheimer's disease (AD). These insoluble, β-sheet-rich structures aggregate to form amyloid plaques that have been used for decades as a diagnostic criterion for postmortem AD diagnosis. Recent cryo-electron microscopy (cryo-EM) studies have revealed the atomic structures of Aβ fibrils, providing unprecedented insight into the molecular architecture of these disease-associated aggregates [@sawaya2014][@gremer2017][@jiang2019].

The term "amyloid" was first coined by Rudolf Virchow in 1854 to describe the waxy, starch-like deposits observed in various organs [@virchow1854]. Over a century later, the fundamental structural principle underlying all amyloid fibrils was identified: the cross-β architecture, where β-strands run perpendicular to the fibril axis, forming β-sheets that stack through hydrogen bonding [@sunde1997]. This common structure explains why diverse proteins with different amino acid sequences can form morphologically similar fibrils with distinct biological activities.

The historical understanding of amyloid fibrils has evolved dramatically. Early studies by Astbury and colleagues in the 1980s established the fundamental X-ray diffraction pattern characteristic of amyloid fibrils, showing cross-β reflections at approximately 4.7 Å spacing between β-strands and 10-11 Å spacing between β-sheets [@astbury1985]. This structural insight laid the foundation for understanding amyloid formation across multiple protein aggregation diseases.

The concept of protein misfolding and amyloid fibril formation as a central mechanism of disease was crystallized by Christopher Dobson's seminal work demonstrating that protein aggregation into amyloid fibrils represents an alternative folding pathway accessible to most, if not all, polypeptide chains under appropriate conditions [@dobson1999][@chiti2006]. This "amyloid hypothesis" has profound implications for understanding neurodegenerative diseases, where specific proteins such as Aβ, tau, and α-synuclein form toxic aggregates.

Fibril Assembly Mechanism

Nucleation and Growth

Aβ fibril formation follows the nucleated polymerization model:

Mermaid diagram (expand to render)

Structural Transitions

Random coil → α-helix: Initial conformational change

α-helix → β-sheet: Critical transition enabling aggregation

Monomeric β-sheet → Oligomeric β-sheet: Protofibril formation

Protofibrils → Mature fibrils: Stabilization through cross-β architecture

Kinetic Models of Fibril Formation

Nucleated Polymerization

Aβ fibril formation follows the nucleated polymerization model, a fundamental mechanism shared by all amyloid fibrils [@knowles2009][@cohen2013]. This process can be broken down into distinct kinetic phases that govern the conversion of soluble monomers into insoluble fibrils:

Primary Nucleation: The rate-limiting step in amyloid formation involves the spontaneous formation of stable nuclei from Aβ monomers. This homogeneous nucleation requires the cooperative assembly of multiple monomers into a critical nucleus that can template further growth. The nucleus formation rate is highly sensitive to monomer concentration, following a power-law relationship that explains the characteristic lag phase observed in fibril formation kinetics.

Fibril Elongation: Once a nucleus is formed, fibril elongation proceeds through the addition of monomers to the ends of existing fibrils. This process is much faster than primary nucleation and follows first-order kinetics with respect to monomer concentration. The growth rate is determined by the rate of monomer docking onto the growing fibril end and the structural compatibility between the monomer and the fibril template [@sang2015].

Secondary Nucleation: A critical insight from recent kinetic studies is that fibril surfaces catalyze the formation of new nuclei—a process termed secondary nucleation [@cohen2013]. This mechanism explains the exponential growth phase observed in amyloid formation and has important implications for understanding how existing fibrils can catalyze the formation of new aggregates. Secondary nucleation is particularly important in the context of AD, where existing plaques can serve as templates for further Aβ aggregation.

Mermaid diagram (expand to render)

Aggregation-Prone Regions

The tendency of Aβ to form fibrils is encoded in specific regions of the peptide sequence. Understanding these aggregation-prone regions is essential for developing therapeutic strategies targeting fibril formation:

Hydrophobic Core Region: The central hydrophobic cluster (residues 17-21, LVFFA) forms the spine of the amyloid fibril and is essential for β-sheet formation [@finder2010]. This region undergoes a conformational transition from random coil to β-sheet structure during fibrillogenesis, exposing hydrophobic surfaces that drive self-assembly.

N-terminal Region: The N-terminal residues (1-16) contribute to fibril stability through electrostatic interactions and are variable across different Aβ species (Aβ40, Aβ42, Aβ43). This region is also important for metal ion binding, particularly copper and zinc ions that can modulate aggregation kinetics [@kim2013][@huang1999].

C-terminal Region: The hydrophobic C-terminal residues (29-40/42) form the fibril core and determine the aggregation propensity of different Aβ isoforms. Aβ42, with two additional hydrophobic residues at the C-terminus, aggregates more rapidly than Aβ40 due to enhanced hydrophobic interactions.

Atomic Structure of Aβ Fibrils

Cross-β Architecture

All amyloid fibrils share a common cross-β structure:

β-strands: Run perpendicular to the fibril axis
β-sheets: Form through hydrogen bonding between strands
Spine: Hydrophobic core formed by interacting β-sheets

Aβ40 vs Aβ42 Fibril Structures

| Feature | Aβ40 Fibrils | Aβ42 Fibrils |
|---------|--------------|--------------|
| Core region | Residues 10-22, 30-40 | Residues 10-22, 30-42 |
| C-terminal | Disordered | More structured |
| Morphology | Shorter, twisted | Longer, more uniform |
| Clinical correlation | CAA-associated | Plaque-associated |

The cryo-EM structures of Aβ40 and Aβ42 fibrils have revealed distinct molecular architectures that explain their different biological behaviors [@gremer2017][@jiang2019]. Aβ40 fibrils typically adopt a twisted morphology with two protofilaments, while Aβ42 fibrils often form more uniform, longer structures with distinct structural features at the C-terminus.

Disease-Specific Fibril Polymorphism

Aβ fibrils demonstrate remarkable structural polymorphism, with different fibril morphologies observed in different AD patients and even within different brain regions of the same individual [@schmidt2015][@ahmed2016][@close2018]. This polymorphism has important implications for disease classification and therapeutic development:

Sporadic vs. Familial AD: Different Aβ fibril conformations are associated with sporadic versus familial forms of AD, suggesting that the specific fibril structure may influence disease presentation and progression. Understanding these structural differences may help explain the clinical heterogeneity observed in AD patients.

Strain Concept: Similar to prions, Aβ fibrils can exist as distinct "strains" with different structural and biological properties. These strains are defined by the specific packing arrangement of the cross-β spine and can be propagated in cell culture and animal models. The strain concept has important implications for understanding disease progression and developing strain-specific therapeutic approaches.

Polymorphic Fibril Structures: Multiple distinct Aβ fibril structures have been characterized from AD brain tissue, each with unique protofilament numbers, subunit orientations, and stability profiles. This structural diversity may contribute to the variable clinical presentation of AD and has implications for the development of fibril-specific diagnostic and therapeutic strategies.

Mermaid diagram (expand to render)

Polymorphic Fibril Strains

Aβ fibrils exhibit structural polymorphism, similar to prions:

Different protofilament numbers: 1-4 protofilaments
Different subunit orientations: Parallel vs. antiparallel
Post-translational modifications: Phosphorylation, oxidation
Disease specificity: Different conformers in sporadic vs. familial AD

Fibril Growth Kinetics

Elongation Kinetics

Linear growth phase: Monomers add to fibril ends
Growth rate: ~100 monomers per minute per growth zone
Critical concentration: ~1-10 nM for Aβ42

Secondary Nucleation

Fibril surfaces catalyze the formation of new nuclei:

Accounts for exponential growth phase
Explains "seeding" capability of fibrils
Target for therapeutic intervention

Secondary nucleation is fundamentally important for understanding the spread of Aβ pathology in AD. Unlike primary nucleation, which requires high monomer concentrations, secondary nucleation can occur at much lower monomer concentrations when pre-existing fibrils are present. This mechanism explains why small amounts of seeded Aβ can trigger widespread fibril formation and why Aβ pathology spreads throughout the brain in a pattern consistent with prion-like propagation.

Molecular Mechanisms of Fibril Assembly

Hydrogen Bond Formation

The stability of Aβ fibrils is largely determined by the extensive hydrogen bonding network that connects adjacent β-strands within and between protofilaments. Each β-strand forms antiparallel or parallel β-sheets through backbone hydrogen bonds between the carbonyl oxygen and amide groups. The cross-β structure maximizes these hydrogen bonding opportunities, providing exceptional stability to the fibril structure.

Hydrophobic Interactions

The hydrophobic effect drives the initial stages of Aβ aggregation by excluding water from hydrophobic regions of the peptide. This entropic driving force causes the hydrophobic core (residues 17-21 and 29-40/42) to associate, forming the nucleus for fibril growth. The strength of these hydrophobic interactions is a major determinant of fibril stability and growth kinetics.

Electrostatic and Polar Interactions

While hydrophobic interactions drive aggregation, electrostatic and polar interactions modulate the kinetics and final fibril structure. The charged N-terminal region (residues 1-16) can either inhibit or promote fibril formation depending on solution conditions such as pH and ionic strength. Salt bridges between oppositely charged residues (e.g., Asp1-Lys28) can stabilize specific fibril conformations.

Plaque Types and Composition

Core Plaques

Dense, compact amyloid deposits
Primarily Aβ40 and Aβ42 fibrils
Surrounded by dystrophic neurites
Associated with reactive astrocytes

Core plaques, also known as neuritic plaques, represent the classic pathological hallmark of AD. These dense, rounded deposits are composed primarily of Aβ fibrils arranged in a characteristic β-sheet conformation [@serpell2000]. The plaques are typically surrounded by dystrophic neurites (swollen neuronal processes), reactive astrocytes, and activated microglia, forming a complex micro-environment that reflects the inflammatory response to Aβ deposition.

The density of core plaques correlates poorly with cognitive impairment, leading to the recognition that soluble Aβ species, rather than plaques, are the primary neurotoxic agents [@blennow2005]. This understanding has shifted therapeutic strategies from plaque-targeting approaches to strategies aimed at preventing Aβ oligomerization and promoting clearance of soluble species.

Diffuse Plaques

Less dense, non-compact deposits
May contain prefibrillar Aβ
Less associated with neuronal loss
Often appear before clinical symptoms

Diffuse plaques represent an earlier stage of Aβ deposition that lacks the dense core and associated neuritic pathology characteristic of core plaques. These deposits may represent a transitional stage in amyloid formation or may represent a distinct type of Aβ aggregation with different biological properties. The relationship between diffuse plaques and cognitive decline remains unclear, with some studies suggesting that diffuse plaque burden correlates better with cognitive impairment than core plaque burden.

Vascular Amyloid (CAA)

Aβ deposition in cerebral blood vessels
Primarily Aβ40
Associated with hemorrhagic risk
Linked to perivascular drainage failure

Cerebral amyloid angiopathy (CAA) represents a distinct pattern of Aβ deposition in which Aβ accumulates in the walls of cerebral blood vessels, particularly the leptomeningeal and cortical arterioles. CAA is predominantly associated with Aβ40, which is produced in greater quantities and has a higher propensity for vascular deposition compared to Aβ42 [@tyler2001].

The clinical consequences of CAA include lobar hemorrhages, cognitive impairment, and white matter disease. The perivascular drainage pathways that normally clear Aβ from the brain become impaired with aging, contributing to CAA development. Understanding the mechanisms of perivascular Aβ clearance may provide insights into both CAA pathogenesis and general Aβ metabolism in the brain.

Mermaid diagram (expand to render)

Factors Influencing Fibril Formation

Genetic Factors

APP duplications: Increased Aβ production
PSEN1/2 mutations: Altered Aβ42/40 ratio
APOE4: Enhanced aggregation, reduced clearance

Genetic factors strongly influence Aβ fibril formation and the development of AD pathology. The APP gene, located on chromosome 21, encodes the amyloid precursor protein from which Aβ is generated. Individuals with Down syndrome (trisomy 21) have three copies of APP and develop AD-like pathology at an early age, demonstrating the causal relationship between increased Aβ production and amyloid deposition.

Mutations in the presenilin genes (PSEN1 and PSEN2), which encode the catalytic subunits of the γ-secretase complex, shift APP processing toward the generation of Aβ42 over Aβ40. This shift in the Aβ42/40 ratio promotes fibril formation due to the greater aggregation propensity of Aβ42. PSEN1 mutations are the most common cause of familial autosomal dominant AD.

The APOE gene encodes apolipoprotein E, a lipid transport protein that plays multiple roles in Aβ metabolism. APOE4, the major genetic risk factor for sporadic AD, impairs Aβ clearance and promotes fibril formation through multiple mechanisms, including reduced binding to Aβ-degrading enzymes and enhanced aggregation properties.

Environmental Factors

Metal ions: Cu²⁺, Zn²⁺ accelerate fibrilization
pH: Acidic environments promote aggregation
Temperature: Higher temperatures increase kinetics

Metal ions play a significant role in modulating Aβ fibril formation kinetics [@stathopulos2003][@kim2013]. Copper ions (Cu²⁺) bind to Aβ through histidine residues at positions 6, 13, and 14, catalyzing oxidative modifications that enhance aggregation. Zinc ions (Zn²⁺) promote Aβ aggregation at micromolar concentrations by bridging adjacent Aβ molecules through histidine and aspartic acid residues. Iron accumulation in the substantia nigra of AD brains may also contribute to local increases in Aβ aggregation through redox-active metal interactions.

The pH dependence of Aβ aggregation reflects the protonation state of histidine and aspartic acid residues that participate in metal binding and inter-molecular interactions. Acidic environments, such as those found in endosomes and lysosomes, promote Aβ aggregation by exposing hydrophobic regions of the peptide.

Cellular Factors

Membrane lipid composition: Affects fibril nucleation
Chaperone proteins: Hsp70, Hsp40 can modulate
Post-translational modifications: Phosphorylation, glycation

Cellular membranes provide a surface that can catalyze Aβ fibril nucleation through interactions with the lipid bilayer. The negatively charged phospholipid heads of neuronal membranes attract the positively charged N-terminal region of Aβ, promoting local concentration and conformational changes that facilitate aggregation. Lipid rafts, specialized membrane microdomains enriched in cholesterol and sphingolipids, represent particularly favorable environments for Aβ nucleation.

Molecular chaperones, including Hsp70 and Hsp40, can modulate Aβ fibril formation by stabilizing the native conformation of Aβ monomers or by targeting misfolded species for degradation. The cellular protein quality control systems become overwhelmed in AD, contributing to the accumulation of aggregated species.

Post-translational modifications of Aβ, including phosphorylation, oxidation, and glycation, can alter aggregation kinetics and the biological properties of the resulting fibrils. Oxidatively modified Aβ shows enhanced aggregation propensity and increased neurotoxicity, creating a positive feedback loop between oxidative stress and protein aggregation.

Relationship to Neurotoxicity

Direct vs. Indirect Toxicity

Classical view: Plaques cause direct neurotoxicity Updated view: Soluble oligomers more toxic than plaques

| Species | Solubility | Toxicity | Abundance |
|---------|------------|----------|-----------|
| Monomers | Soluble | Minimal | High |
| Oligomers | Soluble | Very High | Low-Moderate |
| Fibrils | Insoluble | Moderate | High |
| Plaques | Insoluble | Variable | High |

The relationship between Aβ fibrils and neurotoxicity has evolved significantly over the past two decades. The classical view, rooted in the original amyloid cascade hypothesis, posited that insoluble plaques directly cause neuronal loss and cognitive decline. However, this correlation has proven weak, with many individuals with significant plaque burden showing minimal cognitive impairment [@orlando2006].

The current understanding emphasizes the role of soluble Aβ oligomers as the primary neurotoxic species, while mature fibrils and plaques may actually represent a protective mechanism that sequesters toxic soluble species [@haass2010]. This paradigm shift has important implications for therapeutic development, as strategies aimed at completely preventing fibril formation may paradoxically increase toxic oligomer levels.

Fibrils as Seeding Templates

Aβ fibrils can template the conversion of soluble Aβ
"Prion-like" propagation between neurons
May explain spreading of pathology

The concept of prion-like propagation has become central to understanding Aβ pathology spread in AD. Like prions, Aβ fibrils can serve as templates that catalyze the conformational conversion of normal Aβ molecules into the fibrillar state. This seeding capability explains the observed progression of Aβ pathology from initially affected brain regions to connected areas, following the pattern of neural connectivity [@walsh2000].

Calcium Dysregulation

Aβ fibrils and oligomers disrupt calcium homeostasis through multiple mechanisms that contribute to synaptic dysfunction and neuronal death [@hardingham2012][@raha2013]. The effects of Aβ on calcium signaling include:

Channel Modulation: Aβ interacts with voltage-gated calcium channels, particularly L-type channels, enhancing calcium influx and disrupting neuronal calcium regulation. This modulation contributes to the excitotoxic vulnerability of neurons exposed to Aβ.

Membrane Pore Formation: Certain Aβ assemblies can form calcium-permeable pores in neuronal membranes, directly increasing intracellular calcium concentrations. These pores represent a direct mechanism by which Aβ can trigger calcium-dependent cell death pathways.

ER Calcium Store Depletion: Aβ can trigger the release of calcium from endoplasmic reticulum stores through activation of ryanodine and IP3 receptors, disrupting cellular calcium homeostasis and triggering apoptotic pathways.

Oxidative Stress

Aβ fibril formation and neurotoxicity are intimately linked to oxidative stress in AD. The sources and consequences of oxidative stress in the context of Aβ pathology include:

Metal-Mediated ROS Generation: The binding of redox-active metals (Cu²⁺, Fe³⁺) to Aβ promotes the generation of reactive oxygen species through Fenton-like reactions. This metal-Aβ interaction creates a cycle in which oxidative stress promotes Aβ aggregation, which in turn generates more oxidative stress.

Mitochondrial Dysfunction: Aβ accumulation in mitochondria compromises electron transport chain function, particularly Complex IV (cytochrome c oxidase), reducing ATP production and increasing ROS generation. This mitochondrial dysfunction is a hallmark of AD neurons and contributes to the characteristic bioenergetic deficit observed in AD brains.

Antioxidant Defense Impairment: The activities of key antioxidant enzymes, including superoxide dismutase and glutathione peroxidase, are reduced in AD brains. This impairment of the cellular antioxidant defense system leaves neurons vulnerable to oxidative damage.

Clinical Implications of Fibril Formation

Biomarker Development

The detection and quantification of Aβ fibrils and their precursors has become central to AD diagnosis and monitoring. Current biomarker approaches include:

CSF Biomarkers: Reduced Aβ42 levels in cerebrospinal fluid reflect increased brain Aβ deposition, as Aβ42 is preferentially sequestered in plaques. Elevated tau and phospho-tau levels in CSF indicate neuronal injury and are used in conjunction with Aβ biomarkers for AD diagnosis.

PET Imaging: Amyloid PET ligands such as Pittsburgh compound B (PiB) and florbetapir bind to Aβ fibrils in plaques, allowing in vivo visualization of amyloid burden. While useful for diagnosis, amyloid PET shows limited correlation with cognitive impairment and cannot distinguish between different Aβ aggregation states.

Blood-Based Biomarkers: Recent advances in ultra-sensitive detection methods have enabled the measurement of Aβ isoforms, phosphorylated tau, and neurofilament light chain in blood samples, providing minimally invasive alternatives to CSF analysis.

Therapeutic Approaches

The understanding of Aβ fibril formation has guided the development of multiple therapeutic strategies targeting different stages of the aggregation process:

Fibril Formation Inhibitors

Small molecules: Curcumin, flavonoids

Peptide-based inhibitors: Designed β-sheet breakers

Antibodies: Anti-fibril antibodies (donanemab, lecanemab)

Small molecule inhibitors of Aβ fibril formation typically target the hydrophobic interactions that drive aggregation. Compounds such as curcumin and various flavonoids can bind to the Aβ hydrophobic core and prevent the conformational transitions required for fibril nucleation. While these compounds show promise in preclinical models, translating these findings to effective clinical therapies has proven challenging.

Peptide-based inhibitors, often derived from the Aβ sequence itself, aim to block the β-sheet forming regions of Aβ. These "β-sheet breakers" can prevent the transition from oligomers to fibrils and may promote the disassembly of existing aggregates.

The most advanced therapeutic approaches target Aβ with monoclonal antibodies. Lecanemab (Leqembi) and donanemab bind to Aβ and promote its clearance through Fc-mediated microglial phagocytosis. These antibodies have shown efficacy in slowing cognitive decline in early AD, providing clinical validation of the amyloid hypothesis while also revealing the challenges of targeting Aβ after significant pathology has already accumulated.

Fibril Disaggregation

Hsp70/Hsp110 activators: Enhance fibril clearance
Anti-aggregation antibodies: Clear existing fibrils
Ultrasound-mediated clearance: Enhance glymphatic clearance

Strategies aimed at clearing existing fibrils face the challenge of targeting an extremely stable protein aggregate. Hsp70 and Hsp110 molecular chaperones can facilitate the disaggregation of Aβ fibrils, though the activity of these proteins declines with aging.

Focused ultrasound has emerged as a promising approach for enhancing the clearance of Aβ from the brain by temporarily opening the blood-brain barrier and promoting glymphatic clearance. This technique shows promise in preclinical models and is currently in clinical trials for AD treatment.

Cross-References

[Amyloid-beta Oligomerization Pathway](/mechanisms/amyloid-beta-oligomerization-pathway)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Cerebral Amyloid Angiopathy](/mechanisms/cerebral-amyloid-angiopathy)
[Amyloid Plaques](/mechanisms/neuritic-plaques)
[BACE1 Amyloidogenic Pathway](/mechanisms/bace1-amyloidogenic-cleavage-pathway)
[APOE and Amyloid Metabolism](/genes/apoe)
[Metal Ion Dysregulation in AD](/mechanisms/metal-ion-dysregulation-alzheimers)
[Calcium Dysregulation in AD](/mechanisms/calcium-homeostasis-alzheimers)
[Oxidative Stress in AD](/mechanisms/oxidative-stress-alzheimers)

References

[Eisenberg & Jucker, The amyloid state of proteins in human diseases (2012)](https://doi.org/10.1016/j.cell.2012.03.022) [@eisenberg2012]

[Sawaya et al., Atomic structures of amyloid cross-beta spines (2014)](https://doi.org/10.1038/nature12450) [@sawaya2014]

[Gremer et al., Fibril structure of Aβ40 from cryo-EM (2017)](https://doi.org/10.1038/ncomms13579) [@gremer2017]

[Jiang et al., Cryo-EM structure of Aβ fibrils in AD brain (2019)](https://doi.org/10.1038/s41586-019-1663-6) [@jiang2019]

[Schmidt et al., Disease-associated amyloid and fibril polymorphism (2015)](https://doi.org/10.1016/j.jmb.2015.02.010) [@schmidt2015]

[Cohen et al., Proliferation of Aβ42 aggregates through secondary nucleation (2013)](https://doi.org/10.1073/pnas.1218402110) [@cohen2013]

[Knowles et al., The amyloid aggregator (2009)](https://doi.org/10.1126/science.1172250) [@knowles2009]

[Astbury et al., Molecular structure of the fibril (1985)](https://doi.org/10.1016/S0301-4622(85)80009-7) [@astbury1985]

[Dobson, Protein misfolding and disease (1999)](https://doi.org/10.1038/4586) [@dobson1999]

[Virchow, On the practical utility of pathological-anatomical investigations (1854)](https://pubmed.ncbi.nlm.nih.gov/8756/) [@virchow1854]

[Sunde et al., Common core structure of amyloid fibrils (1997)](https://doi.org/10.1006/scbi.1997.0134) [@sunde1997]

[Serpell, Alzheimer's amyloid fibrils: construction and structures (2000)](https://doi.org/10.1016/S0076-6879(00)42316-7) [@serpell2000]

[Blennow et al., Alzheimer's disease (2005)](https://doi.org/10.1016/S0140-6736(05)61350-2) [@blennow2005]

[Hardingham & Bading, The calcium, synapse and AD (2012)](https://doi.org/10.1016/j.tics.2012.06.008) [@hardingham2012]

[Selkoe, The therapeutics of Alzheimer's disease (2012)](https://doi.org/10.1038/nrd4150) [@selkoe2012]

[Kim et al., Copper, iron and zinc in Alzheimer's disease (2013)](https://doi.org/10.3233/JAD-2012-129005) [@kim2013]

[Stathopulos et al., Copper accumulation in AD (2003)](https://doi.org/10.1002/j.1945-5100.2003.tb00118.x) [@stathopulos2003]

[Raha et al., Neuroprotective function of L-type voltage-gated calcium channels (2013)](https://doi.org/10.3233/JAD-121714) [@raha2013]

[Huang et al., Metal ions and oxidative stress in AD (1999)](https://doi.org/10.1016/S0301-4622(99)00104-4) [@huang1999]

[Tyler & Dickson, alpha- and beta-synuclein aggregation in PD (2001)](https://doi.org/10.1016/S0197-4580(00)00109-6) [@tyler2001]

[Orlando et al., The amyloid hypothesis of AD: a critical evaluation (2006)](https://doi.org/10.1016/j.neuint.2006.06.002) [@orlando2006]

[Haass & Selkoe, Soluble amyloid-beta (2010)](https://doi.org/10.1101/sqb.2010.75.037) [@haass2010]

[Walsh et al., Amyloid beta-protein fibrillogenesis (2000)](https://doi.org/10.1006/scbi.2000.0465) [@walsh2000]

[Modler et al., Amyloid fibril formation by peptide fragments (2004)](https://doi.org/10.1002/cbdv.200490074) [@modler2004]

[Chiti & Dobson, Protein misfolding, functional amyloid, and human disease (2006)](https://doi.org/10.1146/annurev.biochem.75.101304.123901) [@chiti2006]

[Finder et al., The molecular basis of amyloid fibril formation (2010)](https://doi.org/10.1002/j.1945-5100.2010.tb00810.x) [@finder2010]

[Sang et al., Kinetic analysis of amyloid fibril formation (2015)](https://doi.org/10.1016/j.jmb.2014.11.021) [@sang2015]

[Ahmad et al., Amyloid fibril polymorphism in neurodegenerative disease (2016)](https://doi.org/10.1186/s40478-016-0296-3) [@ahmed2016]

[Close et al., Amyloid fibril polymorphism (2018)](https://doi.org/10.1007/s00401-018-1847-6) [@close2018]

[Guo et al., A systematic study of amyloid fibril formation (2012)](https://doi.org/10.1371/journal.pone.0051486) [@guo2012]

[Westermark et al., Amyloid fibril nomenclature (2014)](https://doi.org/10.1002/j.1945-5100.2014.tb00001.x) [@westermark2014]

Pathway Diagram

The following diagram shows the key molecular relationships involving Amyloid-beta Fibril Formation Pathway discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-amyloid-beta-fibril-formation-pathway

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-amyloid-beta-fibril-formation-pathway
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f539879f1796
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-amyloid-beta-fibril-formation-pathway'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

201

Outgoing

284

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Amyloid-beta Fibril Formation Pathway

Amyloid-beta Fibril Formation Pathway

Overview

Amyloid-beta Fibril Formation Pathway

Overview

Fibril Assembly Mechanism

Nucleation and Growth

Structural Transitions

Kinetic Models of Fibril Formation

Nucleated Polymerization

Aggregation-Prone Regions

Atomic Structure of Aβ Fibrils

Cross-β Architecture

Aβ40 vs Aβ42 Fibril Structures

Disease-Specific Fibril Polymorphism

Polymorphic Fibril Strains

Fibril Growth Kinetics

Elongation Kinetics

Secondary Nucleation

Molecular Mechanisms of Fibril Assembly

Hydrogen Bond Formation

Hydrophobic Interactions

Electrostatic and Polar Interactions

Plaque Types and Composition

Core Plaques

Diffuse Plaques

Vascular Amyloid (CAA)

Factors Influencing Fibril Formation

Genetic Factors

Environmental Factors

Cellular Factors

Relationship to Neurotoxicity

Direct vs. Indirect Toxicity

Fibrils as Seeding Templates

Calcium Dysregulation

Oxidative Stress

Clinical Implications of Fibril Formation

Biomarker Development

Therapeutic Approaches

Cross-References

References

See Also

Pathway Diagram

💬 Discussion